Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Clinigence Holdings ( (NUTX) ) is now available.
Clinigence Holdings has filed an auditors’ consent related to Nutex Health Inc.’s consolidated financial statements for the years ending December 31, 2023. This filing, made on November 18, 2025, incorporates these financial statements into previously filed registration statements, potentially impacting stakeholders’ understanding of the company’s financial health.
The most recent analyst rating on (NUTX) stock is a Buy with a $164.00 price target. To see the full list of analyst forecasts on Clinigence Holdings stock, see the NUTX Stock Forecast page.
Spark’s Take on NUTX Stock
According to Spark, TipRanks’ AI Analyst, NUTX is a Outperform.
NUTX’s strong financial performance and undervaluation are the most significant factors driving its score. Positive technical indicators and earnings growth support the stock’s potential, though caution is advised due to historical financial volatility and regulatory concerns.
To see Spark’s full report on NUTX stock, click here.
More about Clinigence Holdings
Average Trading Volume: 138,496
Technical Sentiment Signal: Hold
Current Market Cap: $968.3M
Learn more about NUTX stock on TipRanks’ Stock Analysis page.